drugset / Trial / NCT04969679

Additive Effect of Probiotics (Mutaflor®) in Patients With Ulcerative Colitis on 5-ASA Treatment.

NCT04969679 ↗

Phase 4 Completed 134 enrolled Kangbuk Samsung Hospital
RandomizedParallel-groupDouble-blindTreatment

Summary

E.coli Nissle 1917 (Mutaflor®) is equivalent to mesalazine in preventing disease relapse in ulcerative colitis. However, data on ability of E.coli Nissle 1917 (Mutaflor®) to induce remission compared with placebo is limited. Investigators aim to investigate the efficacy of E.coli Nissle 1917 (Mutaflor®) as an add-on treatment to 5-ASA in mild to moderate ulcerative colitis.

Timeline

Start
2018-03-16
Primary completion
2020-06-03
Completion
2020-06-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator E. coli Nissle 1917 Other / unclassified 2 unknown Oral

Indications